You have full text access to this OnlineOpen article

Cancer

Cover image for Vol. 119 Issue 2

15 January 2013

Volume 119, Issue 2

Pages 247–469

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Original Articles

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      Effect of Massachusetts health insurance reform on mammography use and breast cancer stage at diagnosis (pages 250–258)

      Nancy L. Keating, Elena M. Kouri, Yulei He, Dee W. West and Eric P. Winer

      Article first published online: 25 JUL 2012 | DOI: 10.1002/cncr.27757

      Health insurance reform in Massachusetts is not associated with increased rates of mammography or earlier disease stage at diagnosis compared with California, possibly because of insurance rates and mammography rates that already are high. Additional research is needed to assess the impact of insurance expansions in other populations, especially those with higher uninsurance rates.

    2. Endocrine Disease
      You have full text access to this OnlineOpen article
      The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer (pages 259–265)

      Megan R. Haymart, Mousumi Banerjee, Di Yang, Andrew K. Stewart, Ronald J. Koenig and Jennifer J. Griggs

      Article first published online: 28 JUN 2012 | DOI: 10.1002/cncr.27721

      There is heterogeneity in clinician decision making for the management of patients with thyroid cancer. The specialty of the primary decision maker, the number of providers administering radioactive iodine, and access to a tumor board are associated significantly with the use of radioactive iodine for stage I thyroid cancer.

    3. Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases (pages 266–276)

      Elena Miranda, Paolo Bianchi, Annarita Destro, Emanuela Morenghi, Alberto Malesci, Armando Santoro, Luigi Laghi and Massimo Roncalli

      Article first published online: 11 JUL 2012 | DOI: 10.1002/cncr.27722

      Prognosis and survival in colorectal cancer are mainly associated with the development of distant metastases rather than the primary tumor itself. A comparison of these alterations between primary tumors and distant metastases demonstrates the amount of molecular heterogeneity during colorectal cancer progression and its influence on clinical decision making; in fact, potential prognostic targets should be evaluated carefully for their heterogeneity in both primary tumors and distant metastases to avoid erroneous misclassification.

    4. You have full text access to this OnlineOpen article
      Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer : A single institutional experience (pages 277–284)

      Francesco Leone, Marco Gatti, Paolo Massucco, Federica Colombi, Elisa Sperti, Delia Campanella, Daniele Regge, Pietro Gabriele, Lorenzo Capussotti and Massimo Aglietta

      Article first published online: 6 JUL 2012 | DOI: 10.1002/cncr.27736

      Induction chemotherapy followed by chemoradiation therapy may result in significant disease control in patients with locally advanced pancreatic carcinoma. In the current study, both patients with borderline resectable disease and those with unresectable disease benefit from this treatment, gaining a chance to undergo resection and the possibility of improved overall survival.

    5. You have full text access to this OnlineOpen article
      Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy : A pooled analysis of 6 prospective trials (pages 285–292)

      Todd M. Bauer, Bassel F. El-Rayes, Xiaobai Li, Nazik Hammad, Philip A. Philip, Anthony F. Shields, Mark M. Zalupski and Tanios Bekaii-Saab

      Article first published online: 11 JUL 2012 | DOI: 10.1002/cncr.27734

      Baseline carbohydrate antigen 19-9 (CA19-9) is prognostic for outcomes in patients with pancreatic adenocarcinoma. Change in CA19-9 serum level up to a 5% increase from baseline remains predictive for response to gemcitabine-containing therapy, and thus should be considered a negative predictor.

    6. You have full text access to this OnlineOpen article
      Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma (pages 293–303)

      Ming-Huang Chen, Kun-Ju Lin, Wu-Lung R. Yang, Ya-Wen Kao, Tsung-Wen Chen, Shu-Chaou Chao, Peter Mu-Hsin Chang, Chun-Yu Liu, Cheng-Hwai Tzeng, Yee Chao, Ming-Han Chen, Chun-Nan Yeh and Chi-Ying F. Huang

      Article first published online: 18 JUL 2012 | DOI: 10.1002/cncr.27743

      Cholangiocarcinoma (CCA) is an aggressive tumor with a poor prognosis, and novel drugs for treating CCA need to be identified. The bioinformatic method Connectivity Map was used to identify heat shock protein 90 inhibitors as potential therapeutic agents for CCA.

    7. You have full text access to this OnlineOpen article
      Genome-wide identification of Epstein-Barr virus–driven promoter methylation profiles of human genes in gastric cancer cells (pages 304–312)

      Junhong Zhao, Qiaoyi Liang, Kin-Fai Cheung, Wei Kang, Raymond W. M. Lung, Joanna H. M. Tong, Ka Fai To, Joseph J. Y. Sung and Jun Yu

      Article first published online: 25 JUL 2012 | DOI: 10.1002/cncr.27724

      Aberrant cytosine-guanine dinucleotide hypermethylation profile was demonstrated in Epstein-Barr virus (EBV)-positive gastric cancer cells compared with EBV-negative AGS cells, as analyzed by DNA methylation microarray with 886 hypermethylated genes involved in important cancer-related pathways. Induction of promoter methylation by EBV is regulated by up-regulation of DNA methyltransferase-3b through latent membrane protein 2A.

    8. Genitourinary Disease
      You have full text access to this OnlineOpen article
      Pericyte coverage of differentiated vessels inside tumor vasculature is an independent unfavorable prognostic factor for patients with clear cell renal cell carcinoma (pages 313–324)

      Yun Cao, Zhi-Ling Zhang, Ming Zhou, Paul Elson, Brian Rini, Hakan Aydin, Kristin Feenstra, Min-Han Tan, Bree Berghuis, Rebeka Tabbey, James H. Resau, Fang-Jian Zhou, Bin Tean Teh and Chao-Nan Qian

      Article first published online: 18 JUL 2012 | DOI: 10.1002/cncr.27746

      Higher pericyte coverage in the tumor vasculature is related to more aggressive clinicopathologic characteristics in patients with clear cell renal cell carcinoma. In this study, pericyte coverage is identified as an independent unfavorable prognostic factor.

    9. Gynecologic Oncology
      You have full text access to this OnlineOpen article
      The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy (pages 325–331)

      Suisui Song, Sonali Rudra, Michael D. Hasselle, Paige L. Dorn, Loren K. Mell, Arno J. Mundt, S. Diane Yamada, Nita K. Lee and Yasmin Hasan

      Article first published online: 17 JUL 2012 | DOI: 10.1002/cncr.27652

      The effect of treatment time has not been well studied for cervical cancer patients who were treated in the era of concurrent chemoradiotherapy. This multi-institutional retrospective study found treatment time had a significant impact on pelvic failure, but not on distant failure or disease-specific mortality. A prolonged treatment time was found to be associated with delay in starting brachytherapy and higher incidence of acute grade 3/4 toxicities.

    10. You have full text access to this OnlineOpen article
      BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma (pages 332–338)

      Kathryn P. Pennington, Tom Walsh, Ming Lee, Christopher Pennil, Akiva P. Novetsky, Kathy J. Agnew, Anne Thornton, Rochelle Garcia, David Mutch, Mary-Claire King, Paul Goodfellow and Elizabeth M. Swisher

      Article first published online: 18 JUL 2012 | DOI: 10.1002/cncr.27720

      This study reports comprehensive germline assessment of 30 tumor suppressor genes, including BRCA1 (breast cancer 1, early onset), BRCA2, DNA mismatch repair genes, TP53 (tumor protein p53), and Fanconi anemia-BRCA pathway genes in a large series of uterine serous carcinoma. Approximately 5% of subjects had loss-of-function mutations in 3 different genes, which has implications for defining risk of other cancers and risk to family members.

    11. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma (pages 339–347)

      Darrell White, Adetola Kassim, Birbal Bhaskar, Jing Yi, Karen Wamstad and Virginia E. Paton

      Article first published online: 18 JUL 2012 | DOI: 10.1002/cncr.27745

      The addition of bevacizumab to bortezomib in unselected patients with pretreated multiple myeloma does not result in significant improvements in efficacy outcomes. The combination is well tolerated, and the current results identify no new safety concerns for either agent.

    12. You have full text access to this OnlineOpen article
      First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma (pages 348–355)

      Liang Wang, Zhi-hui Wang, Xiao-qin Chen, Ya-jun Li, Ke-feng Wang, Yun-fei Xia and Zhong-jun Xia

      Article first published online: 18 JUL 2012 | DOI: 10.1002/cncr.27752

      Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is a distinct subtype of natural killer cell lymphoma in which, to date, optimal treatment strategies and prognosis have not been fully defined. Combined gemcitabine, oxaliplatin, and L-asparaginase followed by involved-field radiation therapy can be an effective and feasible treatment strategy for patients with stage IE/IIE ENKTL of the upper aerodigestive tract.

    13. Lung Disease
      You have full text access to this OnlineOpen article
      Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas (pages 356–362)

      Melissa L. Johnson, Camelia S. Sima, Jamie Chaft, Paul K. Paik, William Pao, Mark G. Kris, Marc Ladanyi and Gregory J. Riely

      Article first published online: 18 JUL 2012 | DOI: 10.1002/cncr.27730

      Lung adenocarcinomas can be distinguished by identifying mutated driver oncogenes, including epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma 2 viral oncogene homolog (KRAS). In the largest cohort of patients whose tumors were analyzed for EGFR and KRAS mutations from 1 institution, the authors report that the presence of a KRAS mutation is a poor prognostic factor for advanced lung adenocarcinomas.

    14. Discipline

      Clinical Trials
      You have full text access to this OnlineOpen article
      Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia (pages 363–370)

      Tait D. Shanafelt, Timothy G. Call, Clive S. Zent, Jose F. Leis, Betsy LaPlant, Deborah A. Bowen, Michelle Roos, Kristina Laumann, Asish K. Ghosh, Connie Lesnick, Mao-Jung Lee, Chung S. Yang, Diane F. Jelinek, Charles Erlichman and Neil E. Kay

      Article first published online: 3 JUL 2012 | DOI: 10.1002/cncr.27719

      In this phase 2 trial, daily oral use of the green tea extract epigallocatechin gallate in the Polyphenon E preparation was found to be well tolerated by patients with chronic lymphocytic leukemia. Durable declines in the absolute lymphocyte count and/or lymphadenopathy were observed in the majority of patients.

    15. You have full text access to this OnlineOpen article
      Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma : Southwest Oncology Group Study S0350 (pages 371–379)

      Daruka Mahadevan, Joseph M. Unger, Catherine M. Spier, Daniel O. Persky, Fay Young, Michael LeBlanc, Richard I. Fisher and Thomas P. Miller

      Article first published online: 25 JUL 2012 | DOI: 10.1002/cncr.27733

      In this prospective cooperative group (Southwest Oncology Group) clinical trial, patients were investigated who had rare subtypes of newly diagnosed (approximately 80%) and relapsed/refractory (approximately 20%) peripheral T-cell non-Hodgkin lymphoma (PTCL), for which the standard of care is not established and outcomes are poor. The authors hypothesize that a combination of “non–P-glycoprotein substrate” agents—platinum, etoposide, gemcitabine, and methylprednisolone—will have greater efficacy in these patients than traditionally used cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-like therapies.

    16. You have full text access to this OnlineOpen article
      Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma (pages 380–387)

      Han Chong Toh, Pei-Jer Chen, Brian I. Carr, Jennifer J. Knox, Sharlene Gill, Peter Ansell, Evelyn M. McKeegan, Barry Dowell, Michelle Pedersen, Qin Qin, Jiang Qian, Frank A. Scappaticci, Justin L. Ricker, Dawn M. Carlson and Wei Peng Yong

      Article first published online: 25 JUL 2012 | DOI: 10.1002/cncr.27758

      In this multicenter international phase 2 trial, the compelling clinical activity of linifanib was demonstrated in patients with advanced hepatocellular carcinoma (HCC). Further evaluation in patients with advanced HCC is ongoing.

    17. Disparities Research
      You have full text access to this OnlineOpen article
      Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics (pages 388–394)

      Wong-Ho Chow, Brian Shuch, W. Marston Linehan and Susan S. Devesa

      Article first published online: 12 NOV 2012 | DOI: 10.1002/cncr.27690

      Black Americans not only have higher incidence rates of renal cell carcinoma (RCC) than whites, but also poorer prognosis after RCC diagnosis. The relative survival disadvantage of RCC patients who were black was observed regardless of age, sex, time period of diagnosis, tumor stage or size, histological subtype, or surgical treatment.

    18. You have full text access to this OnlineOpen article
      Adjuvant chemotherapy for stage III colon cancer in the oldest old : Results beyond clinical guidelines (pages 395–403)

      Anasooya Abraham, Elizabeth B. Habermann, David A. Rothenberger, Mary Kwaan, Armin D. Weinberg, Helen M. Parsons, Pankaj Gupta and Waddah B. Al-Refaie

      Article first published online: 17 JUL 2012 | DOI: 10.1002/cncr.27755

      The percentage of persons aged ≥ 75 years who receive adjuvant chemotherapy remains low despite demonstrated survival benefits. The results of the current study support the call for phase II/III studies assessing the toxicities and benefits of adjuvant chemotherapy for elderly patients with American Joint Commission on Cancer stage III colon cancer.

    19. Epidemiology
      You have full text access to this OnlineOpen article
      Type 2 diabetes mellitus and survival in pancreatic adenocarcinoma : A retrospective cohort study (pages 404–410)

      Allen Hwang, Vivek Narayan and Yu-Xiao Yang

      Article first published online: 1 AUG 2012 | DOI: 10.1002/cncr.27731

      This retrospective cohort study attempted to elucidate the relationship between type 2 diabetes mellitus and survival in patients with pancreatic adenocarcinoma. Long-standing type 2 diabetes mellitus (> 5 years) was found to be associated with worse prognosis.

  3. Review Articles

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. Discipline

      Outcomes Research
      You have full text access to this OnlineOpen article
      Recommendations for including multiple symptoms as endpoints in cancer clinical trials : A report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force (pages 411–420)

      Charles S. Cleeland, Jeff A. Sloan, David Cella, Connie Chen, Amylou C. Dueck, Nora A. Janjan, Astra M. Liepa, Rajiv Mallick, Ann O'Mara, Jay D. Pearson, Yasuhiro Torigoe, Xin Shelley Wang, Loretta A. Williams and Jeanie F. Woodruff

      Article first published online: 28 AUG 2012 | DOI: 10.1002/cncr.27744

      The ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force examines the measurement of multiple symptoms as cancer clinical trials outcomes. This report defines a multisymptom outcome; addresses source attribution and the need for a hypothesis-driven, conceptual framework to measure multisymptom outcomes; and recommends methods for using multiple, individual symptom scores or composite scores as outcomes.

  4. Original Articles

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. Discipline

      Psychosocial Oncology
      You have full text access to this OnlineOpen article
      Who makes the decision regarding the treatment of clinically localized prostate cancer–the patient or physician? : Results from a population-based study (pages 421–428)

      Lixin Song, Ronald C. Chen, Jeannette T. Bensen, George J. Knafl, Matthew E. Nielsen, Laura Farnan, Eric M. Wallen, Merle Mishel, Raj S. Pruthi, James L. Mohler and Paul A. Godley

      Article first published online: 11 JUL 2012 | DOI: 10.1002/cncr.27738

      Approximately 87% of the patients in the current population-based study made the decision regarding treatment of clinically localized prostate cancer either by themselves or in collaboration with their physicians. Patient age, cancer aggressiveness, concerns about physical impact, perceptions of having enough time for decision-making, and how much advice was received from others contributed to the decision-making process.

    2. Symptom Control and Palliative Care
      You have full text access to this OnlineOpen article
      General population norms for the Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI) (pages 429–437)

      Zeeshan Butt, John Peipert, Kimberly Webster, Connie Chen and David Cella

      Article first published online: 6 JUL 2012 | DOI: 10.1002/cncr.27688

      The Functional Assessment of Cancer Therapy–Kidney Symptom Index and its subscales have previously been shown to reliably and validly assess the most important symptoms associated with renal cell carcinoma. The authors now provide general population normative data for these scales to aid in score interpretation and planning of future clinical trials.

      Corrected by:

      Erratum: Erratum

      Vol. 119, Issue 9, 1762, Article first published online: 18 JAN 2013

    3. You have full text access to this OnlineOpen article
      Clinical pattern and associations of oxaliplatin acute neurotoxicity : A prospective study in 170 patients with colorectal cancer (pages 438–444)

      Andreas A. Argyriou, Guido Cavaletti, Chiara Briani, Roser Velasco, Jordi Bruna, Marta Campagnolo, Paola Alberti, Francesca Bergamo, Diego Cortinovis, Marina Cazzaniga, Cristina Santos, Konstantinos Papadimitriou and Haralabos P. Kalofonos

      Article first published online: 11 JUL 2012 | DOI: 10.1002/cncr.27732

      The degree of acute oxaliplatin-induced peripheral neuropathy may predispose patients to the development and severity of a chronic, cumulative form of neurotoxicity. Therefore, it may be advisable to test agents against acute oxaliplatin-induced peripheral neuropathy to verify their effects on the chronic form.

    4. Translational Research
      You have full text access to this OnlineOpen article
      An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma : Implications for adjuvant treatment (pages 445–453)

      Sarah B. Fisher, Sameer H. Patel, Pelin Bagci, David A. Kooby, Bassel F. El-Rayes, Charles A. Staley III, N. Volkan Adsay and Shishir K. Maithel

      Article first published online: 8 MAY 2012 | DOI: 10.1002/cncr.27619

      High tumor expression of either ribonucleoside reductase subunit M2 or excision repair cross-complementing gene-1 is associated with reduced recurrence-free survival and overall survival after resection of pancreas adenocarcinoma. These biomarkers may help to personalize adjuvant therapy.

    5. You have full text access to this OnlineOpen article
      Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy (pages 454–462)

      Sarah B. Fisher, Kevin E. Fisher, Sameer H. Patel, Matthew G. Lim, David A. Kooby, Bassel F. El-Rayes, Charles A. Staley III, N. Volkan Adsay, Alton B. Farris III and Shishir K. Maithel

      Article first published online: 3 JUL 2012 | DOI: 10.1002/cncr.27739

      High tumor expression of ribonucleotide reductase subunit 2 (RRM2) or human equilibrative nucleoside transporter 1 (hENT1) is associated with reduced survival after resection of biliary tract malignancy. These biomarkers should be considered when selecting patients for adjuvant treatment and stratifying patients who are enrolled in clinical trials.

  5. Correspondence

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have full text access to this OnlineOpen article
      Dental x-rays and risk of meningioma (page 463)

      Timothy J. Jorgensen

      Article first published online: 18 DEC 2012 | DOI: 10.1002/cncr.27710

    2. You have full text access to this OnlineOpen article
      Dental x-rays and risk of meningioma (page 464)

      Stuart C. White, Charles F. Hildebolt and Alan G. Lurie

      Article first published online: 18 DEC 2012 | DOI: 10.1002/cncr.27709

    3. You have full text access to this OnlineOpen article
    4. You have full text access to this OnlineOpen article
      Dental x-rays and risk of meningioma: Response to Drs. Calnon, Jorgensen, and White (pages 465–466)

      Elizabeth B. Claus, Joseph Wiemels and Margaret Wrensch

      Article first published online: 18 DEC 2012 | DOI: 10.1002/cncr.27708

  6. Erratum

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Review Articles
    5. Original Articles
    6. Correspondence
    7. Erratum
    1. You have free access to this content
      Erratum (pages 467–469)

      Article first published online: 26 JUN 2012 | DOI: 10.1002/cncr.27545

      This article corrects:

      Socioeconomic status and the risk of colorectal cancer

      Vol. 118, Issue 14, 3636–3644, Article first published online: 3 JAN 2012

SEARCH

SEARCH BY CITATION